$3.80
0.53% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US1710774076
Symbol
CDXC

ChromaDex Corporation Stock price

$3.80
+0.31 8.88% 1M
+0.13 3.54% 6M
+2.37 165.73% YTD
+2.35 162.07% 1Y
-2.96 43.79% 3Y
-0.28 6.86% 5Y
+2.72 252.18% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.02 0.53%
ISIN
US1710774076
Symbol
CDXC
Industry

Key metrics

Market capitalization $287.03m
Enterprise Value $262.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 294.67
EV/Sales (TTM) EV/Sales 3.06
P/S ratio (TTM) P/S ratio 3.35
P/B ratio (TTM) P/B ratio 9.29
Revenue growth (TTM) Revenue growth 5.74%
Revenue (TTM) Revenue $85.58m
EBIT (operating result TTM) EBIT $-2.00k
Free Cash Flow (TTM) Free Cash Flow $890.00k
Cash position $27.89m
EPS (TTM) EPS $-0.02
P/E forward 378.00
P/S forward 3.02
EV/Sales forward 2.76
Short interest 6.36%
Show more

Is ChromaDex Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

ChromaDex Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a ChromaDex Corporation forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a ChromaDex Corporation forecast:

Buy
100%

Financial data from ChromaDex Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
86 86
6% 6%
100%
- Direct Costs 34 34
2% 2%
39%
52 52
8% 8%
61%
- Selling and Administrative Expenses 45 45
2% 2%
52%
- Research and Development Expense 5.81 5.81
15% 15%
7%
1.58 1.58
359% 359%
2%
- Depreciation and Amortization 1.58 1.58
12% 12%
2%
EBIT (Operating Income) EBIT 0 0
100% 100%
0%
Net Profit -1.35 -1.35
79% 79%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about ChromaDex Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ChromaDex Corporation Stock News

Neutral
Business Wire
one day ago
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announced that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will participate in a fireside chat moderated by Sean McGowan, Senior Analyst at Roth Capital Partners, at the Lytham Partners Fall 20...
Neutral
Business Wire
7 days ago
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CFO--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Ozan Pamir as Chief Financial Officer. Mr. Pamir will oversee all ChromaDex corporate finance matters, including accounting, strategic financial planning, and engaging with public markets...
Neutral
Business Wire
17 days ago
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, is excited to announce the second wave of intravenous (IV) wellness clinics that will offer pharmaceutical-grade Niagen® (nicotinamide riboside chloride or NRC), branded Niagen+, in intravenous (IV) and injecta...
More ChromaDex Corporation News

Company Profile

Chromadex Corp. is a nutraceutical company. The firm engages in acquiring, developing and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Los Angeles, CA.

Head office United States
CEO Robert Fried
Employees 106
Founded 1999
Website www.chromadex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today